 Home > Medical News > Latest Medical News > New progress in oral SERD: Sanofi and Eli Lilly announce test results

New progress in oral SERD: Sanofi and Eli Lilly announce test results

 Last Update: 2021-08-10
 Source: Internet
 Author: User

Tags

lidocaine oral

1 3 5 trimethylbenzene

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Endocrine therapy (ET) is the main treatment option for ER+ (estrogen receptor positive)/HER2- (HER2 negative) breast cancer patients

Recently, Sanofi’s SAR439859 and Eli Lilly’s LY3484356 have successively announced the results of recent clinical trials, injecting new vitality into the SERD track

First, let's understand what is SERD?

SERD is a kind of small molecule.

Sanofi SAR439859 (Amcenestrant)

SAR439859 is an oral SERD developed by Sanofi

In the AMEERA-1 phase study of pretreated patients with ER+/HER2- advanced breast cancer, once a day (QD) 150-600mg SAR439859 showed an average ER occupancy rate of 94%, plasma concentration> 100 ng/mL and good safety

A prospective, randomized, double-blind phase III study of AMEERA-5 is currently underway to compare SAR439859+pebecili with letrozole+pebecili in patients with advanced, locally recurring, or metastatic ER+/HER2- breast cancer The efficacy and safety

Eli Lilly LY3484356

LY3484356 is an oral SERD developed by Eli Lilly.

As of November 9, 2020, 28 patients have been enrolled (n=24 for breast cancer, n=4 for endometrial cancer), with a dose of 200-1200 mgQD

Treatment of emergent adverse events (TEAEs) are mainly grade 1-2, including nausea (32%), fatigue (25%), and diarrhea (18%)

Oral SERD track players

(Source: ClinicalTrials.

The current global SERD targeted drug market is mainly based on the sales scale of fulvestrant, which has grown from 700 million U.

Reference source:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.